Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-bromo-cyclic AMP (8-Br-cAMP) is a cell-permeable, metabolically stable analog of the intracellular second messenger cyclic adenosine monophosphate (cAMP). It acts as a potent agonist for cAMP-dependent protein kinase (PKA) and the exchange protein directly activated by cAMP (Epac). The substitution of a bromine atom at the 8-position of the adenine ring renders the molecule significantly more resistant to hydrolysis by cyclic nucleotide phosphodiesterases (PDEs) compared to endogenous cAMP, allowing for sustained activation of downstream signaling cascades. In experimental biology, 8-Br-cAMP is widely used to investigate the role of cAMP in diverse physiological processes, including the modulation of ion channels (such as HCN and BK channels), regulation of gene expression via CREB phosphorylation, and the control of cellular functions like decidualization, insulin secretion, and smooth muscle relaxation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-bromo-cyclic AMP.